The Food and Drug Administration (FDA) has initiated a Class II recall for Teva Pharmaceuticals USA, Inc.'s Metoprolol Succinate Extended-Release Tablets (25 mg) due to the product failing to meet dissolution specifications. This recall impacts multiple bottle sizes (100 and 1,000 tablets) distributed nationwide.

Pharmaceutical manufacturers and distributors must ensure they have identified and segregated affected product lots. Compliance with recall procedures, including notification to downstream parties and potential return or destruction of recalled product, is required. While specific compliance deadlines are not detailed, the ongoing nature of the recall necessitates prompt action to mitigate potential patient risk and regulatory non-compliance.